Acutaas Chemicals Ltd.
NSE: ACUTAASAcutaas Chemicals Ltd.: A 30-second snapshot
Acutaas Chemicals (Pharma) trades at ₹2,731 — up 33.22% over the past 3 months and 49.9% above its 200-day moving average of ₹1,821 — with a trailing PE of 78.12, the highest among 6 tracked sector peers. FY26 results showed PAT of ₹356 Cr and Q4 PAT growth of 114% YoY, with management guiding 25% growth for FY27; however, the multi-year persistence record shows zero FCF-positive years and a consistency score of 35/100, indicating the strong recent results have not yet translated into a sustained earnings track record.
P/E
78.1
Forward P/E
40.0
ROE
+23.5%
Debt / Equity
2.08
Profit Margin
+25.8%
Div. Yield
+0.1%
5Y ROE > 15%
0/5
5Y FCF > 0
0/5
Quality
54/100
News
6 headlines · 3 positive · 1 negative
Acutaas Chemicals Reports Record ₹356.4 Cr FY26 Profit Fueled by CDMO, Diversification - Whalesbook
Whalesbook
Acutaas Chemicals FY26 Results: PAT INR356 Cr, Guides 25% FY27 Growth - scanx.trade
scanx.trade
Acutaas Chemicals Q4 FY26: PAT Surges 114%, Revenue at ₹4,328 Mn - scanx.trade
scanx.trade
Acutaas Chemicals' (NSE:ACUTAAS) Earnings Are Of Questionable Quality - simplywall.st
simplywall.st
Acutaas Chemicals Schedules Investor Conferences in Mumbai, Hong Kong, Singapore, and London - scanx.trade
scanx.trade
Recent context
- ·FY26 full-year PAT of ₹356 Cr was described as a record, driven by CDMO business and diversification; Q4 PAT growth of 114% YoY with revenue of ₹4,328 Mn; management guided 25% growth for FY27 (source: Whalesbook, scanx.trade, May 2026).
- ·Simplywall.st published a piece questioning the quality of ACUTAAS earnings (May 8, 2026) — this directionally aligns with the persistence data showing zero FCF-positive years despite the reported profit margin of 25.8%.
- ·The company scheduled investor conferences across Mumbai, Hong Kong, Singapore, and London (reported May 15, 2026), suggesting active institutional engagement ahead of what appears to be a broadening investor base.
Strengths
- +ROE of 23.52% ranks 1st among 6 sector peers, with Cipla and Dr. Reddys reporting ROE of 11.74% and 11.84% respectively.
- +Quality score of 61 ranks 1st among all 6 peers in the sector comparison (nearest peer: MAXHEALTH at 54).
- +5-year revenue growth of 43.9% and 5-year earnings growth of 105.6% reflect a substantial expansion phase, with Q4 FY26 revenue at ₹4,328 Mn and PAT surging 114% YoY.
- +Price is 13.7% above the 50-day moving average (₹2,402) and 49.9% above the 200-day moving average (₹1,821), with RSI at 61.54 in the neutral range — not yet in technically overbought territory.
Weaknesses
- −Multi-year persistence is structurally unvalidated: roeYearsAbove15 = 0 and fcfPositiveYears = 0 over the years available, with a consistency score of 35/100 — the strong trailing metrics lack a corroborating multi-year cash generation record.
- −D/E of 2.08 with a rising debt trend; zero FCF-positive years in the persistence record means debt servicing relies on earnings continuing at the current pace without demonstrated free cash flow support.
- −Trailing PE of 78.12 is the highest among 6 sector peers; forward PE of 40.04 implies the market is pricing in substantial and sustained earnings growth — any shortfall against the guided 25% FY27 growth would compress this multiple.
- −Nearest support levels (₹2,073–₹2,055) are approximately 24–25% below current price, with no identified resistance above — leaving a wide gap between current price and the nearest historical floor.
Open questions
- ?If FCF-positive years in the persistence record remain at zero, what is the mechanism by which the company intends to service its rising debt load — and does management guidance address this specifically?
- ?The forward PE of 40.04 implies a significant de-rating from the trailing PE of 78.12 — how much of the guided 25% FY27 earnings growth is already reflected in the current price?
- ?Given that ROE of 23.52% ranks first among peers but the consistency score is 35/100, is the ROE improvement structural (CDMO mix, pricing power) or concentrated in a single year or segment?
- ?With nearest support 24–25% below the current price and no identified resistance above, what factors define the historical price range for this stock, given its limited public trading history?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| ACUTAAS | Acutaas Chemicals Ltd.You're viewing | 78.1 | +23.5% | 61 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.5 | +11.8% | 17 |
Technical state
Current price
₹2,731.00
SMA 50
₹2,402.62
SMA 200
₹1,821.30
RSI (14)
61.5 (neutral)
From 52w high
-4.2%
1Y return
—
3M return
+33.2%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- highFundamental persistence is structurally weak: roeYearsAbove15 = 0 and fcfPositiveYears = 0 with a consistencyScore of 35/100, meaning the reported trailing ROE of 23.52% and profit margin of 25.8% are not corroborated by multi-year data — the profitability record appears concentrated in a very short window.
- highDebt-to-equity of 2.08 with a rising debt trend, combined with zero FCF-positive years in the persistence record; this leverage profile is elevated relative to pharma peers and amplifies risk if earnings growth disappoints.
- mediumTrailing PE of 78.12 is the highest among all 6 sector peers (ranked 6th of 6); nearest comparables trade at PE of 26.5–72.5, and the forward PE of 40.04 embeds very high earnings growth expectations over the next 12 months.
- mediumNearest support cluster (₹2,073–₹2,055) is approximately 24–25% below the current price of ₹2,731; with no resistance levels identified above, historical price reference points for the upside are absent.
- lowNews sample is limited to 6 articles; one piece from simplywall.st specifically questioned the quality of reported earnings, which directionally aligns with the persistence data showing zero FCF-positive years.
Cross-section contradictions
- Trailing ROE of 23.52% and 5-year earnings growth of 105.6% contrast with zero years of ROE above 15% and zero FCF-positive years in the persistence record — headline profitability metrics and multi-year cash generation data point in opposite directions.
- Price is up 33.22% over 3 months and within 4.2% of its 52-week high, while fundamental consistency scores only 35/100 with rising debt and no FCF track record — price momentum and quality fundamentals are diverging.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days